ZevaquenabantAlso known as MRI-1867
Hybrid inhibitor of peripheral CB1 and iNOS, studied in mice in models of fibrosis and dyslipidaemia.
C₂₅H₂₁ClF₃N₅O₂S
CAS 1998760-00-1
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 548.00 g/mol
Updated on
In plain terms
Zevaquenabant (MRI-1867) blocks both the CB1 receptor and an enzyme that produces nitric oxide, iNOS; it is designed to act outside the brain. In mice, it attenuated models of skin and lung fibrosis and of dyslipidaemia. It remains an experimental compound, with no marketing authorisation.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to Zevaquenabant: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Zevaquenabant.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Inverse agonistno measured value cited
high-affinity antagonist/inverse agonist, peripherally restricted (Kumari et al. 2024); the (R) enantiomer inactive at CB1; no Ki value in the texts consulted
- iNOSInhibitorno measured value cited
hybrid iNOS inhibitor; the (R) enantiomer retains this activity (Roger et al. 2020); no numerical value in the texts consulted
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of Zevaquenabant, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
Zevaquenabant, known in the literature as MRI-1867 or S-MRI-1867, is a hybrid inhibitor: a peripherally restricted antagonist and inverse agonist of CB1 and an inhibitor of iNOS (Kumari et al. 2024; Zawatsky et al. 2021). It was designed at the NIAAA/NIH by the team of Kunos, Iyer and Cinar. In mice, simultaneous inhibition of both targets gave a greater antifibrotic efficacy than inhibition of either target alone in models of liver, lung and kidney fibrosis (Zawatsky et al. 2021). In bleomycin-induced skin fibrosis, the compound attenuated established fibrosis in mice lacking the MDR1 and BCRP transporters, but not in C57BL/6 mice: the skin concentration of MRI-1867, an MDR1 substrate, was 0.023 µM in the latter against 8.8 µM in the former, bleomycin increasing MDR1 efflux activity in fibrotic skin (Zawatsky et al. 2021). In bleomycin-induced pulmonary fibrosis, pulmonary delivery of 0.5 mg/kg/day was as effective as systemic delivery of 10 mg/kg/day and matched nintedanib; the compound also attenuated fibrosis and pro-fibrotic mediators in human lung slices (Basu et al. 2025). In obese mice, the (S) enantiomer reduced hepatic steatosis and hepatic VLDL secretion (Roger et al. 2020). The data are preclinical; no clinical data were found in the sources consulted.
Key sources.
- Kumari et al., Nat Commun 2024: structural mechanism of CB1 binding to peripheral and biased inverse agonists (cryo-EM structures with MRI-1867) (new tab)PMID 39695122
- Zawatsky et al., Front Endocrinol 2021: the peripheral hybrid CB1 and iNOS antagonist MRI-1867 shows antifibrotic efficacy in bleomycin-induced skin fibrosis (new tab)PMID 34650521
- Roger et al., Diabetes 2020: simultaneous inhibition of peripheral CB1 and iNOS attenuates obesity-related dyslipidaemia ((S)-MRI-1867 and the (R) enantiomer inactive at CB1) (new tab)PMID 32680936
- Padilha et al., Biomed Pharmacother 2023: in vitro and in vivo pharmacokinetic characterisation, chiral conversion and PBPK modelling of S-MRI-1867 (new tab)PMID 37890204
- Cinar, Iyer and Kunos, Pharmacol Ther 2020: therapeutic potential of second- and third-generation CB1 antagonists (new tab)PMID 31926199
- Basu et al., JCI Insight 2025: CB1 antagonism in profibrotic alveolar macrophages attenuates pulmonary fibrosis (new tab)PMID 40608428
- PubChem, zevaquenabant, CID 155321421 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
History
- Source
- Entirely synthetic compound with no known natural occurrence. It comes from NIH pharmaceutical research and is not marketed (no marketing authorisation found).
Origin
Research tool
No known biosynthetic pathway: a synthetic molecule. It is a dihydropyrazole carboximidamide of (S) configuration, (NE,4S)-N-(1-aminoethylidene)-5-(4-chlorophenyl)-4-phenyl-N'-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide (name read on PubChem, CID 155321421).
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. The compound is in preclinical development; no marketing authorisation was found.
- France
Not classified: zevaquenabant does not appear in the ANSM consolidated list of narcotics (updated 16/02/2026); on a literal reading, its structure (a sulfonylated dihydropyrazole carboximidamide) falls within none of the generic families of Annex IV (indol-3-yl methanones, indazol-3-yl methanones, naphthoylpyrroles, indole or indazole carboxylates and carboxamides, cyclohexylphenols, benzo[c]chromene nucleus). The compound is a drug candidate in development; no marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Kumari et al., Nat Commun 2024: structural mechanism of CB1 binding to peripheral and biased inverse agonists (cryo-EM structures with MRI-1867) (new tab)PMID 39695122
- Zawatsky et al., Front Endocrinol 2021: the peripheral hybrid CB1 and iNOS antagonist MRI-1867 shows antifibrotic efficacy in bleomycin-induced skin fibrosis (new tab)PMID 34650521
- Roger et al., Diabetes 2020: simultaneous inhibition of peripheral CB1 and iNOS attenuates obesity-related dyslipidaemia ((S)-MRI-1867 and the (R) enantiomer inactive at CB1) (new tab)PMID 32680936
- Padilha et al., Biomed Pharmacother 2023: in vitro and in vivo pharmacokinetic characterisation, chiral conversion and PBPK modelling of S-MRI-1867 (new tab)PMID 37890204
- Cinar, Iyer and Kunos, Pharmacol Ther 2020: therapeutic potential of second- and third-generation CB1 antagonists (new tab)PMID 31926199
- Basu et al., JCI Insight 2025: CB1 antagonism in profibrotic alveolar macrophages attenuates pulmonary fibrosis (new tab)PMID 40608428
- PubChem, zevaquenabant, CID 155321421 (identifiers and properties) (new tab)
- ANSM, consolidated list of narcotics, updated 16 February 2026 (text reviewed) (new tab)
- Council Framework Decision 2004/757/JHA, annex, consolidated version of 12 January 2026 (EUR-Lex) (new tab)
Identifiers
Names
- Common name
- Zevaquenabant (MRI-1867)
- IUPAC name
- (NE,4S)-N-(1-aminoethylidene)-5-(4-chlorophenyl)-4-phenyl-N'-[4-(trifluoromethyl)phenyl]sulfonyl-3,4-dihydropyrazole-2-carboximidamide
- Other names
- MRI-1867 · S-MRI-1867 · INV-101 · Zevaquenabant
Identifiers
- Formula
- C₂₅H₂₁ClF₃N₅O₂S
- CAS
- 1998760-00-1
- PubChem CID
- 155321421(new tab)
- InChIKey
- NLXIJZHFEOSWPU-JOCHJYFZSA-N
- SMILES
- CC(=
N) N= C(NS(= O) (= O) c1ccc(C(F) (F) F) cc1) N1C[C@H] (c2ccccc2) C(c2ccc(Cl) cc2) = N1
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.